Comparing the current results to its competitors, Gossamer Bio Inc reported Revenue decrease in the 2 quarter 2026 year on year by -19.59 %, despite the revenue increase by the most of its competitors of 10.78 %, recorded in the same quarter.
Gossamer Bio Inc 's Comment on Competition and Industry Peers
The company competes with major and specialty pharmaceutical and biotechnology firms, academic research institutions, governmental agencies, and other public and private research organizations. Its product candidates face competition from existing and emerging therapies, with key competitive factors including efficacy, safety, convenience, cost, promotional efforts, and intellectual property protection. In the pulmonary arterial hypertension (PAH) indication, competition for seralutinib and RT234 includes prostanoids and prostacyclin receptor agonists such as Orenitram and Tyvaso (United Therapeutics), Uptravi (Janssen), and Yutrepia (Liquidia). For pulmonary hypertension associated with interstitial lung disease (PH-ILD), competitors include investigational drugs such as L606 (Liquidia/Pharmosa Biopharma Inc.), sirolimus (OrphAI Therapeutics), treprostinil palmitil inhalation powder (Insmed, Inc.), mosliciguat (Pulmovant, Inc.), mirivadelgat (ForeSee Pharmaceuticals Co., Ltd.), APL-9796 (Apollo Therapeutics Ltd), and ROC-101 (AllRock Bio, Inc.). Currently, there are no approved therapies for PH-ILD in the European Union, nor are there approved therapies for as-needed use to provide rapid, on-demand symptom relief.
June 10, 2024
Gossamer Bio s Strategic Moves in the Face of Market Expectations San Diego-based Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company, has recently made significant strides in its journey focused on the development and commercialization of seralutinib for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). On a notable front, the company s Compensation Committee approved an inducement grant under Nasdaq Listing Rule 5635(c)(4). This grant, effective June 5, 2024, represents a strategic move aimed at enhancing its talent pool with a non-qualified stock option targeted at a new non-executive employee. Key Facts1...
June 7, 2024
Pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) are severe and potentially life-threatening conditions affecting the pulmonary vasculature. As current treatment options often provide limited efficacy, there is a critical need for new and innovative therapies. In this article, we will focus on the recent developments in the field of PAH and PH-ILD treatment, specifically examining the clinical-stage biopharmaceutical company Gossamer Bio, Inc. and their revolutionary drug, seralutinib. Furthermore, we will explore Gossamer Bio s collaboration with Chiesi Group, a significant player in the biopharmaceutical industry.1. Gossamer Bio Announces I...
May 6, 2024
Pulmonary hypertension is a life-threatening condition characterized by high blood pressure in the arteries of the lungs, causing difficulty breathing and limited physical activity. With this collaboration, Gossamer and Chiesi Group aim to drive global healthcare innovation by harnessing the potential of Seralutinib, demonstrating a shared commitment to addressing unmet patient needs on a global scale.This collaboration taps into a growing global focus on lung health in the aftermath of the COVID-19 pandemic. According to research reports, PAH alone affects 15 to 50 individuals per million of the global population, and thus modern treatments like Seralutinib become vital for improving the quality of life for...
May 3, 2024
CSIMarket.com is delighted to highlight the latest milestone from the biopharmaceutical universe. In recent news from the clinical-stage biopharmaceutical company, Gossamer Bio, Inc., one can witness a significant stride towards a new breakthrough in the pharmacological treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).Published in the Lancet Respiratory Medicine Journal, the TORREY Phase 2 study illuminates the potential role of the drug seralutinib for treating these two critical respiratory conditions. The biopharmaceutical industry has been eagerly anticipating updates since Gossamer Bio initially announced its commitment to ...
Legend Biotech Corporation is a biotech company focused on developing innovative cell therapies and gene therapies to address unmet medical needs in various diseases.
Madrigal Pharmaceuticals Inc's business model is focused on developing and commercializing innovative therapeutic solutions for liver diseases, with a particular emphasis on non-alcoholic steatohepatitis (NASH) and other metabolic diseases. They aim to provide effective treatments to address unmet medical needs and improve patient outcomes in these areas.
Mineralys Therapeutics Inc is a biotechnology company that follows the business model of developing and commercializing novel therapeutics for various diseases. They focus on discovering and advancing small molecule drugs based on innovative research approaches. Their business model is centered around conducting preclinical and clinical trials, obtaining regulatory approvals, and ultimately bringing their therapeutic products to market for improved patient outcomes.
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.
Sources:
Gossamer Bio Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Gossamer Bio Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
